Lupin Partners with Sandoz to Market Biosimilar Ranibizumab in Multiple Regions

Mumbai-based drug maker Lupin on Tuesday announced a partnership with Switzerland’s Sandoz Group AG to commercialise its biosimilar ranibizumab in select global markets.

As per the agreement, Sandoz will handle the commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.

Lupin will be responsible for manufacturing the biosimilar and managing all regulatory submissions. The company said the collaboration will help expand access to the treatment in key international markets.

Ranibizumab is widely used for the treatment of various eye disorders, including age-related macular degeneration.